|

Iparomlimab and Tuvonralimab Clinical Trials

9 actively recruiting trials

▲ +2 trials since May 2026

Also known as: QL1706, with or without 6 cycles of platinum (carboplatin AUC 5 or cisplatin 75 mg/m²) plus docetaxel (75 mg/m²) or paclitaxel (135-175 mg/m²)

Pipeline

Phase 2: 8

Top Sponsors

  • Sun Yat-sen University2
  • The Second Affiliated Hospital of Hainan Medical University1
  • Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University1
  • Shandong Cancer Hospital and Institute1
  • RenJi Hospital1

Indications

  • Cancer9
  • Liver Disease1
  • Neoplasm Recurrence, Local1
  • First-line Treatment Failure Nasopharyngeal Carcinoma1
  • HR-positive,HER2-negative Breast Cancer1

Other9 trials

A Study Investigating the Efficacy and Safety of the Combination of Iparomlimab and Tuvonralimab With or Without Chemotherapy in Second-line and Subsequent Treatments for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
N/A
Iparomlimab and Tuvonralimab Combined With Nimotuzumab in Recurrent or Metastatic NPC After First-line Treatment Failure: A Single-arm Phase IIa Clinical Trial
Phase 2
Iparomlimab and Tuvonralimab With Chemoradiation for the Treatment of Locally Recurrent and Oligometastatic Cervical Cancer
Phase 2
Iparomlimab and Tuvonralimab in HNSCC
Phase 2
Neoadjuvant QL1706 in Patients With Hormone Receptor Positive, HER2-negative Breast Cancer
Phase 2
Neoadjuvant Radiotherapy Plus Tegafur, Oxaliplatin and Iparomlimab and Tuvonralimab in Resectable Gastric and GE-junction Cancer : A Randomized, Two-arm, Prospective Trial (TRIUNITE-05)
Phase 2
Neoadjuvant Therapy of Iparomlimab and Tuvonralimab Combined With Lenvatinib for Hepatocellular Carcinoma
Phase 2
Safety and Efficacy of Fruquintinib Plus Nab-Paclitaxel and Iparomlimab and Tuvonralimab Injection in the Second-Line Treatment for Immunotherapy-experienced Advanced Gastric Cancer
Phase 2
Safety and Efficacy of IB-FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal Cancer
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.